Myocardial perfusion imaging in Takayasu arteritis

Cloé Comarmond1, Odile Dessault, Jean-Yves Devaux

  • 1From the Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié Salpétrière, Department of Internal Medicine, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Saint-Antoine, Department of Nuclear Medicine, Université Pierre et Marie Curie; AP-HP, Hôpital Saint-Louis, Department of Biostatistics, Université Denis Diderot; AP-HP, Groupe Hospitalier Pitié Salpétrière, Department of Cardiology, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié Salpétrière, Department of Vascular Surgery, Université Pierre et Marie Curie, Paris, France.

Summary

Takayasu arteritis (TA) often causes myocardial perfusion defects. Dipyridamole (DPM) improved these defects in most patients, suggesting microcirculatory dysfunction plays a key role in TA-related myocardial ischemia.